These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37944023)

  • 1. Revolutionizing Tuberculosis Treatment: Uncovering New Drugs and Breakthrough Inhibitors to Combat Drug-Resistant
    Verma A; Naik B; Kumar V; Mishra S; Choudhary M; Khan JM; Gupta AK; Pandey P; Rustagi S; Kakati B; Gupta S
    ACS Infect Dis; 2023 Dec; 9(12):2369-2385. PubMed ID: 37944023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
    Mi J; Gong W; Wu X
    Biomed Res Int; 2022; 2022():5099312. PubMed ID: 35252448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-resistant strains of
    Schami A; Islam MN; Belisle JT; Torrelles JB
    Front Cell Infect Microbiol; 2023; 13():1274175. PubMed ID: 38029252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.
    Jackson M; McNeil MR; Brennan PJ
    Future Microbiol; 2013 Jul; 8(7):855-75. PubMed ID: 23841633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future development of antitubercular chemotherapy.
    Kremer LS; Besra GS
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis.
    Craggs PD; de Carvalho LPS
    Curr Opin Microbiol; 2022 Oct; 69():102191. PubMed ID: 35970040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TB drug discovery: addressing issues of persistence and resistance.
    Smith CV; Sharma V; Sacchettini JC
    Tuberculosis (Edinb); 2004; 84(1-2):45-55. PubMed ID: 14670345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azetidines Kill Multidrug-Resistant
    Cui Y; Lanne A; Peng X; Browne E; Bhatt A; Coltman NJ; Craven P; Cox LR; Cundy NJ; Dale K; Feula A; Frampton J; Fung M; Morton M; Goff A; Salih M; Lang X; Li X; Moon C; Pascoe J; Portman V; Press C; Schulz-Utermoehl T; Lee S; Tortorella MD; Tu Z; Underwood ZE; Wang C; Yoshizawa A; Zhang T; Waddell SJ; Bacon J; Alderwick L; Fossey JS; Neagoie C
    J Med Chem; 2024 Feb; 67(4):2529-2548. PubMed ID: 38331432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of GlgE as a new target for tuberculosis.
    Kalscheuer R; Jacobs WR
    Drug News Perspect; 2010 Dec; 23(10):619-24. PubMed ID: 21180647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives on the treatment of mycobacterial infections using antibiotics.
    He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
    Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis treatment-shortening.
    Singh V
    Drug Discov Today; 2024 May; 29(5):103955. PubMed ID: 38548262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.